OTCM
DVHGF
Market cap13mUSD
Oct 06, Last price
4.94USD
Name
Devonian Health Group Inc
Chart & performance
P/E
—
P/S
—
EPS
—
Div yield, %
—
Shrs. gr., 5y
—
Rev. gr., 5y
%
Revenues
17m
Net income
-4m
CFO
-901k
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Devonian Health Group Inc. specializes in the creation of botanical-based pharmaceutical drugs. Its leading product candidate, Thykamine, is currently undergoing Phase IIa clinical trials to treat conditions such as ulcerative colitis and atopic dermatitis. The company's development pipeline also includes Pantoprazole Magnesium for addressing gastric or duodenal ulcers, Cleo-35 targeting hormonal acne in women, and a range of value-added dermo-cosmetic products. Beyond its own development efforts, Devonian acquires licenses for and distributes various pharmaceutical and health products. Furthermore, the company has established a strategic partnership with CannTx Life Sciences Inc. to collaborate on the development of cannabinoid-based pharmaceutical drugs. Devonian Health Group Inc. was founded in 2015 and is based in Québec, Canada.
Key people
Colette Laurin
Interim Chief Financial Officer, Controller
Dennis Turpin
Chief Financial Officer, Director · since 2026
Pierre Montanaro
President of Altius · since 2024
Erick Shields
Chief Commercial Officer of Altius Heatlcare Inc · since 2023
Andre Boulet
Chairman of the Board, Chief Operating Officer, Chief Scientific Officer · since 2024
Luc Gregoire
President, Chief Executive Officer, Director · since 2023
Director · since 2025
David Baker
Independent Director · since 2024
Edward Dahl
Independent Director · since 2023
Louis Flamand
Independent Director · since 2017
Kathryn Gregory
Independent Director · since 2024
Valuation
Title in thousands, except ratios and share amounts | FY |
|---|---|
| 2025‑07 | |
| Income | |
Revenues | |
Cost of revenue | |
Unusual Expense (Income) | |
NOPBT | |
NOPBT Margin | |
Operating Taxes | |
Tax Rate | |
NOPAT | |
Net income | |
Dividends | |
Dividend yield | |
Proceeds from repurchase of equity | |
BB yield | |
| Debt | |
Debt current | |
Long-term debt | |
Deferred revenue | |
Other long-term liabilities | |
Net debt | |
| Cash flow | |
Cash from operating activities | |
CAPEX | |
Cash from investing activities | |
Cash from financing activities | |
FCF | |
| Balance | |
Cash | |
Long term investments | |
Excess cash | |
Stockholders' equity | |
Invested Capital | |
ROIC | |
ROCE | |
| EV | |
Common stock shares outstanding | |
Price | |
Market cap | |
EV | |
EBITDA | |
EV/EBITDA | |
Interest | |
Interest/NOPBT |